EBV: Entry immunology and oncogenesis

Epstein-Barr virus (EBV) is an important human pathogen, being prevalent in all populations worldwide. Primary infection and subsequent persistence is usually clinically silent, although in some cases primary infection can cause infectious mononucleosis. Importantly, EBV is also a tumour virus and is linked to around 200,000 cases of cancer annually.

Birmingham has been at the forefront of EBV research since 1983. It   hosts one of the largest groupings of researchers working on both basic and translational aspects of Epstein-Barr virus. The scope of this research is broad-ranging, including: studying mechanisms of viral entry into different cell types, elucidating the interactions between infected cells and host immune-responses, and determining the complex mechanisms of oncogenesis of different EBV-associated malignancies.

Current principal investigators active in EBV research are: